eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Thornton & Ross Ltd

Telephone: +44 (0)1484 842217
Fax: +44 (0)1484 847301
WWW: http://www.thorntonandross.com
Medical Information Direct Line: +44(0)1484 848 251
Medical Information e-mail: phv@thorntonross.co.uk
Customer Care direct line: +44(0)1484 842 217
Medical Information Fax: +44(0)1484 847 301

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 10/11/2011
SPC Acriflex 0.25% w/w Chlorhexidine Gluconate Cream


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Acriflex (0.25% w/w Chlorhexidine Gluconate) Cream


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Acriflex (0.25% w/w Chlorhexidine Gluconate) Cream contains:

Chlorhexidine Gluconate 20% solution BP 1.25% v/w.

For excipients, see 6.1.


Go to top of the page
3. PHARMACEUTICAL FORM

Cream for topical administration to human beings.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For the treatment of minor burns and scalds, scratches, cuts and abrasions, sunburn blisters and infected cracked skin.


Go to top of the page
4.2 Posology and method of administration

For general use, apply freely and smooth gently into the skin. For cuts abrasions, burns etc. spread freely and, if necessary, cover with a dressing.

There are no recommended dosage schedules as the product is for use as needed.


Go to top of the page
4.3 Contraindications

Hypersensitivity to any of the ingredients.


Go to top of the page
4.4 Special warnings and precautions for use

Keep away from the eyes.

Avoid contact with the brain, meninges and middle ear. Not for use in body cavities.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

No harmful effects in human pregnancy have been reported. Nevertheless, like all medicines, care should be exercised during pregnancy and lactation.


Go to top of the page
4.7 Effects on ability to drive and use machines

None known.


Go to top of the page
4.8 Undesirable effects

Skin irritation may occur occasionally. Rarely, generalised allergic reactions to chlorhexidine have been reported.


Go to top of the page
4.9 Overdose

Overdosage is extremely unlikely. Chlorhexidine is poorly absorbed and systemic effects are unlikely even if large amounts are swallowed. However, gastric lavage followed by supportive measures may be used as appropriate.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Chlorhexidine is a bisbiguanide disinfectant which is effective against a wide range of vegetative gram-positive and gram-negative bacteria.


Go to top of the page
5.2 Pharmacokinetic properties

Not applicable.


Go to top of the page
5.3 Preclinical safety data

Not applicable.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Arlatone 983 S

Cetostearyl Alcohol BP

Liquid Paraffin BP

Dimeticone 20 BPC

Glycerol BP

Quinoline Yellow Lake 250

Purified Water BP


Go to top of the page
6.2 Incompatibilities

None known.


Go to top of the page
6.3 Shelf life

Three years unopened.


Go to top of the page
6.4 Special precautions for storage

None stated.


Go to top of the page
6.5 Nature and contents of container

Internally lacquered aluminium, blind end tubes containing 25gm and 30gm of product, closed with a polyolefin cap in a cardboard outer.


Go to top of the page
6.6 Special precautions for disposal and other handling

None stated.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Thornton & Ross Limited

Linthwaite

Huddersfield

West Yorkshire

HD7 5QH

United Kingdom


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 00240/0116


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

31 March 2003


Go to top of the page
10. DATE OF REVISION OF THE TEXT

20th October 2003


Go to top of the page
11 DOSIMETRY

Not Applicable


Go to top of the page
12 INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS

Not Applicable



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/25282/SPC/


Active Ingredients/Generics

 
   chlorhexidine gluconate